Navigation Links
Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals' Lorcaserin Achieved Statistically Significant Weight Loss
Date:5/26/2011

ISTANBUL, May 26, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today presented meta-analyses of the three trials in the lorcaserin Phase 3 clinical trial program at ECO 2011, the 18th European Congress on Obesity. The analyses show that lorcaserin caused statistically significant weight loss compared to placebo at one year among 7,500 obese and overweight, diabetic and non-diabetic adults. The lorcaserin-mediated weight loss was associated with favorable changes in biomarkers that may be predictive of cardiovascular and metabolic risk and in quality of life.

Christen M. Anderson, M.D., Ph.D., Arena's Vice President, Lorcaserin Development, stated, "We are pleased to have the opportunity to share and discuss the results from the lorcaserin Phase 3 program with the European medical community at ECO, and we look forward to submitting a Marketing Authorization Application for regulatory approval of lorcaserin in Europe next year."

At one year, using Modified Intent-to-Treat with Last Observation Carried Forward analysis (MITT-LOCF) of the integrated results, 46.3% of lorcaserin 10 mg twice daily (BID) patients and 40.6% of lorcaserin 10 mg once daily (QD) patients achieved at least 5% weight loss, compared to 22.1% of patients on placebo, and 22.0% of lorcaserin 10 mg BID patients and 17.3% of lorcaserin 10 mg QD patients achieved at least 10% weight loss, compared to 8.3% of patients on placebo. Of the patients completing year one of the trials, 62.3% of lorcaserin 10 mg BID patients and 52.8% of lorcaserin 10 mg QD patients achieved at least 5% weight loss, compared to 32.0% of patients on placebo, and 33.5% of lorcaserin 10 mg BID patients and 25.5% of lorcaserin 10 mg QD patients achieved at least 10% weight loss, compared to 13.8% of patients on placebo. Notably, this meta-analysis included approximately 600 patients enrolled with type 2 diabetes, a
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pivotal Phase 3 Study Published in The New England Journal of Medicine (NEJM) Finds Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer is Significantly Improved with ZYTIGA™ (abiraterone acetate)
2. Ardea Biosciences Provides Additional Results From a Phase 2b Study of Lesinurad in Combination With Allopurinol at the Annual European Congress of Rheumatology
3. InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
4. Sinovac Reports Positive Phase I Clinical Trial Results for EV71 Vaccine Candidate Against Hand, Foot & Mouth Disease(HFMD)
5. KemPharm, Inc. Announces Positive Results from Phase 1 Trial of KP201 for Pain
6. Onyx Pharmaceuticals Announces Updated Pivotal Carfilzomib Phase 2B Data
7. ViroPharma Initiates Phase 2 Study of VP 20621 for Prevention of Recurrence of Clostridium difficile Infection (CDI)
8. Families of Spinal Muscular Atrophy Announces Repligen Corporation Receives FDA Approval to Begin Phase I Clinical Trial in SMA
9. EntreMed ENMD-2076 Phase 2 Data to Be Presented at ASCO Annual Meeting
10. Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting
11. Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/17/2013)... Valeant Pharmaceuticals International, Inc. (NYSE: VRX and ... prospectus supplement to its effective shelf registration statement on Form ... regulatory authorities in each of the provinces of ... its common shares to raise gross proceeds of approximately $1.75 ... to the underwriters of the Offering an option, exercisable for ...
(Date:6/17/2013)... , June 17, 2013 The following is ... The Partnership at Drugfree.org :   Last ... that it was halting the sale of prescription drug paraphernalia ... we recognize that from time to time there may be ... our customer. As a result of this misinterpretation we are ...
(Date:6/17/2013)... TORONTO , June 17, 2013 /PRNewswire/ ... that it entered into a securities purchase agreement with ... have agreed to purchase in a private placement an ... non-voting Series E 9% Convertible Preferred Stock ("convertible preferred ... of 100% of the shares of its common stock ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Public Offering Of Common Shares 2Valeant Pharmaceuticals Announces Public Offering Of Common Shares 3Valeant Pharmaceuticals Announces Public Offering Of Common Shares 4A Win for Families: Urban Outfitters Halts Prescription Drug Paraphernalia Product Sales 2Generex Announces $1,225,000 Capital Investment 2Generex Announces $1,225,000 Capital Investment 3Generex Announces $1,225,000 Capital Investment 4Generex Announces $1,225,000 Capital Investment 5
(Date:6/18/2013)... 2013 Healthcare Solutions , ... Procura Management, today announced the appointment of Richard ... In this position, Leonardo will direct Healthcare Solutions’ ... strategic growth initiatives. , Recognized in the property ... Leonardo brings more than 20 years of experience ...
(Date:6/18/2013)... 18, 2013 New York magazine named 145 ... its “Best Doctors” list, up from 129 last year and ... new issue also lists 52 additional doctors who serve at ... strategic growth trajectory. The “Best Doctors” issue, which this year ... 24 print issue and is available online at http://www.nymag.com/bestdoctors ...
(Date:6/18/2013)... at University Hospitals Case Medical Center enrolled their first ... trial evaluating a novel, less-invasive procedure to help clear ... Every year, more than 300,000 people in the United ... carotid artery. If left untreated, these blockages can slow ... a potentially disabling stroke, also known as a "brain ...
(Date:6/18/2013)... Medicare penalties on hospitals with higher-than-expected rates of ... hospitals are evaluating the most accurate methods for ... appearing in the June issue of the ... finds that the American College of Surgeons National ... more accurate data tracking than another popular database, ...
(Date:6/18/2013)... Atlanta, GA (PRWEB) June 18, 2013 ... founder of the Atlanta Vision Institute, is pleased to ... the next generation of Intralase LASIK equipment, the iFS™ ... the only LASIK practice in Atlanta to offer its ... Dr. Ashraf is giving his patients a complimentary upgrade ...
Breaking Medicine News(10 mins):Health News:Healthcare Solutions Appoints Richard Leonardo to Chief Sales Officer 2Health News:Mount Sinai Tops the List in New York Magazine’s 2013 “Best Doctors” Issue 2Health News:Mount Sinai Tops the List in New York Magazine’s 2013 “Best Doctors” Issue 3Health News:UH Case Medical Center among first to enroll patients for global carotid artery trial 2Health News:ACS NSQIP® data is more accurate than administrative data for tracking 30-day hospital readmissions 2Health News:ACS NSQIP® data is more accurate than administrative data for tracking 30-day hospital readmissions 3Health News:ACS NSQIP® data is more accurate than administrative data for tracking 30-day hospital readmissions 4Health News:Atlanta LASIK Surgeon Offers New LASIK Technology 2
... (Nasdaq: HSKA ) announces the following Webcast: , What: ... Year-End 2008 Earnings Conference Call on the ... (MST], Where: www.heska.com (click on the Q4 and Year-End 2008 ... on the front page of this website)., How: ...
... University and Baxter Healthcare Corporation will create a ... announced today. , Under the three-year renewable agreement, ... levels for each year may reach approximately $1 ... levels on a case-by-case basis. Aligned with Baxter,s ...
... French . -->, ,Researchers ... Health Centre (RI MUHC) and the McGill University and Gnome ... Belgian institutions, have discovered DNA variations in a gene that ... in the January issue of the journal Nature Genetics ...
... Jan. 8 /PRNewswire-USNewswire/ -- Advocates for ... and reproductive health, has released an analysis showing ... lag far behind those in France, Germany, and ... , The U.S. teen birth rate, for example, ...
... Health Information Community brings together public-private sector ... networkWASHINGTON, Jan. 8 The National eHealth ... launched today in Washington, D.C. The ... dedicated to the creation of a secure, ...
... could indicate an epidemic of skin cancer, researchers suggest ... of the deadly skin cancer melanoma are increasing among ... older men, researchers report. , Whether the increase in ... However, the rate is increasing among all Americans and ...
Cached Medicine News:Health News:Webcast Alert: Heska Announces Fourth Quarter and Year-End 2008 Earnings Conference Call Webcast 2Health News:Baxter and Northwestern University partner to target new life sciences projects 2Health News:McGill researchers discover gene that increases susceptibility to Crohn's disease 2Health News:McGill researchers discover gene that increases susceptibility to Crohn's disease 3Health News:U.S. Continues to Lag Behind European Countries in Teen Sexual Health - Cleveland Sex Ed Initiative Takes Promising Science-Based Approach 2Health News:U.S. Continues to Lag Behind European Countries in Teen Sexual Health - Cleveland Sex Ed Initiative Takes Promising Science-Based Approach 3Health News:National eHealth Collaborative Launched 2Health News:National eHealth Collaborative Launched 3Health News:National eHealth Collaborative Launched 4Health News:National eHealth Collaborative Launched 5Health News:National eHealth Collaborative Launched 6Health News:Melanoma Rates on the Rise in U.S. 2Health News:Melanoma Rates on the Rise in U.S. 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: